rs17419023

Variant summary

Our verdict is Benign. The variant received -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS2

The NM_001385875.1(ZFYVE27):​c.126C>T​(p.Leu42Leu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00712 in 1,613,914 control chromosomes in the GnomAD database, including 53 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0051 ( 4 hom., cov: 32)
Exomes 𝑓: 0.0073 ( 49 hom. )

Consequence

ZFYVE27
NM_001385875.1 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 0.392

Publications

5 publications found
Variant links:
Genes affected
ZFYVE27 (HGNC:26559): (zinc finger FYVE-type containing 27) This gene encodes a protein with several transmembrane domains, a Rab11-binding domain and a lipid-binding FYVE finger domain. The encoded protein appears to promote neurite formation. A mutation in this gene has been reported to be associated with hereditary spastic paraplegia, however the pathogenicity of the mutation, which may simply represent a polymorphism, is unclear. [provided by RefSeq, Mar 2010]
ZFYVE27 Gene-Disease associations (from GenCC):
  • hereditary spastic paraplegia 33
    Inheritance: AD Classification: LIMITED, NO_KNOWN Submitted by: Labcorp Genetics (formerly Invitae), ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -17 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.49).
BP6
Variant 10-97738603-C-T is Benign according to our data. Variant chr10-97738603-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 238205.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.392 with no splicing effect.
BS2
High AC in GnomAd4 at 768 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ZFYVE27NM_001385875.1 linkc.126C>T p.Leu42Leu synonymous_variant Exon 2 of 13 ENST00000684270.1 NP_001372804.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ZFYVE27ENST00000684270.1 linkc.126C>T p.Leu42Leu synonymous_variant Exon 2 of 13 NM_001385875.1 ENSP00000506975.1

Frequencies

GnomAD3 genomes
AF:
0.00507
AC:
770
AN:
151912
Hom.:
4
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00116
Gnomad AMI
AF:
0.00110
Gnomad AMR
AF:
0.00688
Gnomad ASJ
AF:
0.00173
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00248
Gnomad FIN
AF:
0.00123
Gnomad MID
AF:
0.0132
Gnomad NFE
AF:
0.00840
Gnomad OTH
AF:
0.00482
GnomAD2 exomes
AF:
0.00489
AC:
1229
AN:
251496
AF XY:
0.00532
show subpopulations
Gnomad AFR exome
AF:
0.00160
Gnomad AMR exome
AF:
0.00515
Gnomad ASJ exome
AF:
0.000595
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00176
Gnomad NFE exome
AF:
0.00708
Gnomad OTH exome
AF:
0.00831
GnomAD4 exome
AF:
0.00734
AC:
10723
AN:
1461880
Hom.:
49
Cov.:
33
AF XY:
0.00724
AC XY:
5264
AN XY:
727242
show subpopulations
African (AFR)
AF:
0.00105
AC:
35
AN:
33480
American (AMR)
AF:
0.00521
AC:
233
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.000727
AC:
19
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39694
South Asian (SAS)
AF:
0.00435
AC:
375
AN:
86258
European-Finnish (FIN)
AF:
0.00176
AC:
94
AN:
53418
Middle Eastern (MID)
AF:
0.00832
AC:
48
AN:
5768
European-Non Finnish (NFE)
AF:
0.00853
AC:
9480
AN:
1112006
Other (OTH)
AF:
0.00727
AC:
439
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.466
Heterozygous variant carriers
0
640
1280
1920
2560
3200
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
372
744
1116
1488
1860
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00505
AC:
768
AN:
152034
Hom.:
4
Cov.:
32
AF XY:
0.00461
AC XY:
343
AN XY:
74350
show subpopulations
African (AFR)
AF:
0.00116
AC:
48
AN:
41442
American (AMR)
AF:
0.00687
AC:
105
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.00173
AC:
6
AN:
3464
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5164
South Asian (SAS)
AF:
0.00248
AC:
12
AN:
4834
European-Finnish (FIN)
AF:
0.00123
AC:
13
AN:
10612
Middle Eastern (MID)
AF:
0.0141
AC:
4
AN:
284
European-Non Finnish (NFE)
AF:
0.00839
AC:
570
AN:
67944
Other (OTH)
AF:
0.00429
AC:
9
AN:
2098
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
45
89
134
178
223
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00652
Hom.:
7
Bravo
AF:
0.00501
Asia WGS
AF:
0.00144
AC:
5
AN:
3478
EpiCase
AF:
0.00921
EpiControl
AF:
0.00889

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary spastic paraplegia 33 Benign:2
Dec 05, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not provided Benign:2
Dec 01, 2022
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ZFYVE27: BP4, BP7, BS2 -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Spastic paraplegia Benign:1
Jan 06, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Jun 25, 2015
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.49
CADD
Benign
6.7
DANN
Benign
0.88
PhyloP100
0.39
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs17419023; hg19: chr10-99498360; COSMIC: COSV100519453; API